ClinicalTrials.gg
Active, not recruitingNCT05163041Updated Jan 15, 2026

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

A Phase 1/2 interventional study of BT7480 and Nivolumab in Advanced Solid Tumor, sponsored by BicycleTx Limited. Active, not recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by BicycleTx Limited · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression.

The main goals of the study are to:

  • Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab
  • Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab
  • Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body
  • Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function
Read the detailed description

BT7480 is a tumor targeted immune cell agonist consisting of three bicyclic peptides (Bicycle®) conjugated via a linker, one that binds selectively to Nectin-4 and two that bind to CD137.

This study is a Phase 1/2, multicenter, first-in-human, open-label study of BT7480 given as a single agent and in combination with nivolumab once weekly. There are five parts to the trial: 1) Phase 1 dose escalation in patients with select advanced solid tumors primarily to evaluate safety and tolerability of BT7480 as a monotherapy and determine a recommended Phase 2 dose (RP2D); 2) Phase 1 dose escalation in combination with nivolumab, once the monotherapy RP2D has been determined; 3) Phase 2 dose expansion as a monotherapy once the RP2D has been determined; 4) Phase 2 dose expansion in combination with nivolumab; 5) Phase 1 monotherapy dose confirmation in patients with renal insufficiency once the monotherapy RP2D has been determined

02

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Advanced Solid Tumor
03

In context

Lead sponsor

BicycleTx Limited is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have locally advanced or disease that is to standard therapy, or for which no standard therapy is judged to be appropriate or provide clinical benefit, as judged by the Investigator
  • Must have a or cytologically confirmed malignant solid tumor associated with Nectin-4 expression, including, but not limited to, urothelial (transitional cell) carcinoma; head and neck squamous cell carcinoma; non-small cell lung cancer; and ovarian, breast, gastric, or esophageal carcinoma
  • Must have performance status score 0 or 1 and acceptable organ and hematological function
  • Must have metastatic or locally advanced disease and per (RECIST) 1.1
  • ≥12 weeks
  • Must submit fresh or
  • Must provide written , according to local guidelines, signed and dated by the patient or by a legal guardian prior to the performance of any study-specific procedures, sampling, or analysis

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with a cytotoxic, small molecule, or other systemic chemotherapy within 14 days of the first dose of study drug
  • Prior immunotherapy, including monoclonal antibodies, within 28 days or 5 half-lives of the first dose of study drug, whichever is shorter
  • Prior treatment with CD137 targeted therapy
  • Mean resting (eg, QTcF) greater than 470 msec on triplicate (ECGs) obtained at screening
  • Uncontrolled symptomatic
  • Uncontrolled diabetes with glycosylated greater than or equal to 8%
  • Uncontrolled hypertension at screening or prior to initiation of study drug
  • History of disease except well-controlled diabetes mellitus, alopecia, well controlled thyroid disease or vitiligo
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    BT7480 monotherapy dose escalation

    Participants will receive increasing doses of BT7480. It is expected that approximately 80 patients will participate in this dose escalation arm.

    Drug: BT7480

  • Experimental
    BT7480 and nivolumab dose escalation

    Participants will receive increasing doses of BT7480 and standard dose of nivolumab. It is expected that approximately 12 patients will participate in this dose escalation arm.

    Drug: BT7480 · Drug: Nivolumab

  • Experimental
    BT7480 monotherapy dose expansion

    Participants will receive a selected dose of BT7480. It is expected that approximately 45 patients will participate in this dose expansion arm in Phase 2.

    Drug: BT7480

  • Experimental
    BT7480 and nivolumab dose expansion

    Participants will receive a selected dose of BT7480 and standard dose of nivolumab. It is expected that approximately 45 patients will participate in this dose expansion arm in Phase 2.

    Drug: BT7480 · Drug: Nivolumab

  • Experimental
    BT7480 monotherapy in patients with renal insufficiency

    Participants will receive a selected dose of BT7480. It is expected that approximately 12 patients will participate in this dose confirmation arm.

    Drug: BT7480

Interventions

  • DrugBT7480

    Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle

  • Nivolumab will be given as a 240mg dose every 2 weeks administered as per local labelling as a 30 minute IV infusion

06

What researchers measure

Primary outcomes

  1. Number of patients with treatment emergent adverse events in dose escalation phase

    Incidence and severity of treatment emergent adverse events to assess safety and tolerability following treatment with BT7480 alone and in patients with renal insufficiency using NCI CTCAE v5.0 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 (+/-5) days after the last dose of study drug

  2. Number of patients with treatment emergent adverse events in dose escalation phase

    Incidence and severity of treatment emergent adverse events to assess safety and tolerability following treatment with BT7480 and in combination with nivolumab using NCI CTCAE v5.0 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) until 125 (+/-5) days after the last dose of study drug

  3. Confirmed response rate as measured by overall response rate (ORR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phase

    Overall response rate (ORR) following treatment with BT7480 alone and in combination with nivolumab according to RECIST 1.1 criteria nivolumab according to RECIST 1.1 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  4. Confirmed response rate as measured by clinical benefit rate (CBR) to demonstrate clinical activity following treatment with BT7480 in dose expansion phase

    Clinical benefit rate (CBR) following treatment with BT7480 alone and in combination with nivolumab according to RECIST 1.1 criteria nivolumab according to RECIST 1.1 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

Secondary outcomes

  1. Confirmed response rate as measured by overall response rate (ORR) to demonstrate clinical activity following treatment with BT7480 in dose escalation phase

    Overall response rate (ORR) following treatment with BT7480 alone and in combination with nivolumab and in patients with renal insufficiency according to RECIST 1.1 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  2. Confirmed response rate as measured by clinical benefit rate (CBR) to demonstrate clinical activity following treatment with BT7480 in dose escalation phase

    Clinical benefit rate (CBR) following treatment with BT7480 alone and in combination with nivolumab and in patients with renal insufficiency according to RECIST 1.1 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  3. Number of patients with treatment emergent adverse events in dose expansion phase

    Incidence and severity of treatment emergent adverse events to assess safety and tolerability following treatment with BT7480 alone using NCI CTCAE v5.0 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) until 30 (+/-5) days after the last dose of study drug

  4. Number of patients with treatment emergent adverse events in dose expansion phase

    Incidence and severity of treatment emergent adverse events to assess safety and tolerability following treatment with BT7480 alone using NCI CTCAE v5.0 criteria

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) until 125 (+/-5) days after the last dose of study drug

  5. Duration of response to assess clinical activity in dose escalation and dose expansion phase

    Duration of response following treatment with BT7480 alone and in combination with nivolumab and in patients with renal insufficiency

    Time frame: From initial response to therapy to subsequent disease progression, an average of 6 months

  6. Progression free survival time in dose escalation and dose expansion phase

    Duration of time from first drug administration to disease progression according to RECIST 1.1 following treatment with BT7480 alone and in combination with nivolumab and in patients with renal insufficiency

    Time frame: At 6 months

  7. Maximum plasma concentration (Cmax) of BT7480

    Maximum plasma concentration (Cmax) of BT7480 in all participants receiving BT7480 alone or in combination with nivolumab

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  8. Area under the plasma concentration-time curve (AUC) of BT7480

    Area under the plasma concentration-time curve (AUC) of BT7480 in all participants receiving BT7480 alone or in combination with nivolumab

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  9. Terminal half life (t1/2) of BT7480 in plasma

    Terminal half life (t1/2) of BT7480 in plasma in all participants receiving BT7480 alone or in combination with nivolumab

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  10. Cumulative amount of BT7480 excreted in the urine

    Cumulative amount of BT7480 excreted in the urine in all participants receiving BT7480 alone or in combination with nivolumab

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  11. Number of participants positive for anti-drug antibodies (ADA)

    Incidence of ADAs in patients treated with BT7480 alone or in combination with nivolumab

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

  12. Level of CD137 target engagement in all patients

    Level of CD137 target engagement in peripheral blood in patients treated with BT7480 alone or in combination with nivolumab

    Time frame: From Cycle 1 Day 1 (each cycle is 28 days) through study completion, an average of 6 months

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Aug 2026, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2021
First posted
Dec 20, 2021
StartActual
Nov 2, 2021
Primary completionEst.
Aug 2026
CompletionEst.
Dec 2026
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05163041
Lead sponsor
BicycleTx Limited
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Nov 2, 2021
Primary completion
Aug 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion